Personal

Ticket to Biotech

No refunds will be administered. Be sure that you're an accepted T2B member before paying for your ticket.

***If you're a T2B member and do not receive your confirmation within 1 business day of RSVPing (above), check your email spam folder. The automated Luma email includes the cal invite.***

If you're not part of Ticket to Biotech, 

, and join before registering for this event:

It's our final community mixer of the year! Don't miss this chance to mix and mingle with our incredible community of biopharma communicators at Novo Holdings' office in Boston.

This come-and-go networking event is open to all biopharma communicators in the T2B community. Complimentary snacks and drinks will be provided.

Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation.  Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk and Novonesis and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seed, Venture, Growth, Planetary Health Investments and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development.  As of year-end 2025, Novo Holdings had total assets of USD 109 billion.

Q4 T2Bmeet @ Boston 2026